News | January 12, 2022
Covaxin booster neutralises Omicron and Delta variants: Study
The study will be published on the pre-print server, medRXiv, shortly
The study will be published on the pre-print server, medRXiv, shortly
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Subscribe To Our Newsletter & Stay Updated
